Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding: 2019-2024

Historic Shares Outstanding for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $45.8 million.

  • 4D Molecular Therapeutics' Shares Outstanding fell 10.05% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year decrease of 10.05%. This contributed to the annual value of $45.8 million for FY2024, which is 6.31% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Shares Outstanding stood at $45.8 million for FY2024, which was up 6.31% from $43.1 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Shares Outstanding high stood at $45.8 million for FY2024, and its period low was $26.7 million during FY2020.
  • Its 3-year average for Shares Outstanding is $40.5 million, with a median of $43.1 million in 2023.
  • Data for 4D Molecular Therapeutics' Shares Outstanding shows a peak YoY soared of 415.20% (in 2020) over the last 5 years.
  • Over the past 5 years, 4D Molecular Therapeutics' Shares Outstanding (Yearly) stood at $26.7 million in 2020, then climbed by 20.77% to $32.2 million in 2021, then increased by 1.25% to $32.6 million in 2022, then soared by 32.02% to $43.1 million in 2023, then rose by 6.31% to $45.8 million in 2024.